Safety and Long-Term Efficacy of Forehead Contouring With a Polycaprolactone-Based Dermal Filler.

[BACKGROUND] Recently, a biostimulatory dermal filler based on polycaprolactone (PCL) microspheres was introduced. To our knowledge, no report has examined the safety and efficacy of PCL-based dermal fillers in forehead augmentation.

[OBJECTIVE] To evaluate the safety and efficacy of forehead augmentation using a PCL-based dermal filler.

[MATERIALS AND METHODS] The study population consisted of 58 patients (57 women, 98%; 1 man, 2%), aged 20 to 65 years, undergoing forehead augmentation using a PCL-based dermal filler between October 2013 and October 2015 at our clinic. The physicians used the Global Aesthetic Improvement Scale (GAIS) to evaluate its efficacy 1, 3, 6, 12, and 24 months postoperatively.

[RESULTS] The mean GAIS score at 1, 3, 6, 12, and 24 months was 2.14 ± 0.95, 2.38 ± 0.77, 2.50 ± 0.76, 2.45 ± 0.52, and 2.33 ± 0.50, respectively. The scores increased markedly from 1 to 3 months and were maintained at 24 months.

[CONCLUSION] A PCL-based dermal filler is a good option for soft tissue augmentation of the forehead, as it is safe and has long-lasting favorable cosmetic efficacy.